Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Spyre Therapeutics, Inc.AGLE · Entity 2649 | Director | August 13, 2018 | August 15, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Spyre Therapeutics, Inc.
Report date August 13, 2018 · Filed August 15, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 175,861 |
Ending reported balance
After 2018-08-13 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2018-08-13 · Exercise / conversion · Acquired 17,333 · Balance 155,861 Row 2 · 2018-08-13 · Exercise / conversion · Acquired 20,000 · Balance 175,861 |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.28 · Expires 2026-05-16 | Direct | 6,667 |
Reported balance
After 2018-08-13 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-08-13 · Exercise / conversion · Disposed 17,333 · Balance 6,667 F1: The stock option vested and became exercisable, and shall continue to vest and become exercisable, in 36 equal monthly installments beginning on June 17, 2016, until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.73 · Expires 2027-11-30 | Direct | 10,000 |
Reported balance
After 2018-08-13 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2018-08-13 · Exercise / conversion · Disposed 20,000 · Balance 10,000 F2: The stock option vested and became exercisable, and shall continue to vest and become exercisable, in 12 equal monthly installments beginning on January 1, 2018 until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vested and became exercisable, and shall continue to vest and become exercisable, in 36 equal monthly installments beginning on June 17, 2016, until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date.
F2: The stock option vested and became exercisable, and shall continue to vest and become exercisable, in 12 equal monthly installments beginning on January 1, 2018 until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 13, 2018 Filed Aug 15, 2018 16:40 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | Exercise / conversionDirector Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $4.73 | $0.00 |
DisclosureSEC source: 0001567619-18-001186 · doc1.xml · derivative · entry 4 GEORGIOU GEORGE · CIK 0000749811 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 20,000 shares Expires 2027-11-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option vested and became exercisable, and shall continue to vest and become exercisable, in 12 equal monthly installments beginning on January 1, 2018 until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
| August 13, 2018 Filed Aug 15, 2018 16:40 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | Exercise / conversionDirector Stock Option (right to buy) · Derivative | 17,333 | $0.00 Strike: $7.28 | $0.00 |
DisclosureSEC source: 0001567619-18-001186 · doc1.xml · derivative · entry 3 GEORGIOU GEORGE · CIK 0000749811 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,667 Underlying: Common Stock · 17,333 shares Expires 2026-05-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option vested and became exercisable, and shall continue to vest and become exercisable, in 36 equal monthly installments beginning on June 17, 2016, until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
| August 13, 2018 Filed Aug 15, 2018 16:40 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | Exercise / conversionCommon Stock | 20,000 | $4.73 | $94,600.00 |
DisclosureSEC source: 0001567619-18-001186 · doc1.xml · nonDerivative · entry 2 GEORGIOU GEORGE · CIK 0000749811 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,861 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 13, 2018 Filed Aug 15, 2018 16:40 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | Exercise / conversionCommon Stock | 17,333 | $7.28 | $126,184.24 |
DisclosureSEC source: 0001567619-18-001186 · doc1.xml · nonDerivative · entry 1 GEORGIOU GEORGE · CIK 0000749811 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,861 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 07, 2018 Filed Jun 8, 2018 18:44 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | GrantDirector Stock Option (right to buy) · Derivative | 18,400 | $0.00 Strike: $10.28 | $0.00 |
DisclosureSEC source: 0001140361-18-027928 · doc1.xml · derivative · entry 1 GEORGIOU GEORGE · CIK 0000749811 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,400 Underlying: Common Stock · 18,400 shares Expires 2028-06-06 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 12 equal monthly installments beginning on July 7, 2018 until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
| December 01, 2017 Filed Dec 5, 2017 21:01 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | GrantDirector Stock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $4.73 | $0.00 |
DisclosureSEC source: 0001140361-17-045123 · doc1.xml · derivative · entry 1 GEORGIOU GEORGE · CIK 0000749811 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2027-11-30 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 12 equal monthly installments beginning on January 1, 2018 until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.